Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet
Print
Odin J. Naderer, PharmD
Vice President Clinical Pharm & Trans Med
Chimerix, Inc.
Poster(s):
054: The Effect of Moderate Hepatic Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
143: The Effect of Severe Renal Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET